Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDROMEDA: AZD9750 as monotherapy and in combination in metastatic prostate cancer
2024-516976-14-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of AZD9750 in prostate cancer (PCa) (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities in Part A, Adverse events and serious adverse events and 3 more. Started Mar 2026; status: completed.
02
Drugs
AZD9750
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-516976-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516976-14-00.